TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02329899

Intervention type: OTHER
Intervention: Second step of investigations
Description: Second step according to results of the first step:~* exploration of coagulation factors;~* factor XIII and fibrinolysis investigations;~* investigation of platelet function;~* investigation of thrombocytopenia.

Intervention type: OTHER
Intervention: Second step of investigations
Description: Second step according to results of the first step:~* exploration of coagulation factors;~* factor XIII and fibrinolysis investigations;~* investigation of platelet function;~* investigation of thrombocytopenia.
Study: NCT02948738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Asthma Education
Description: Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Asthma Education
Description: Basic review of asthma action plan and inhaler use
Study: NCT04198077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0
Study: NCT01445080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study: NCT03724552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial LED Therapy (Participants ages 18-59)
Description: Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
Study: NCT02479022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin 320
Description: Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
Study: NCT02104726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy guided steroid injection
Description: We want to compare if there is a difference between the two arms, with the assumption that with fluoroscopy will deliver the steroid more accurately and see better outcomes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blind Steroid Injection
Description: Want to compare it to fluoroscopy guided, with assumption that it will be less effective in reducing pain
Study: NCT04364152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task walking training
Description: Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task walking training
Description: Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
Study: NCT00420524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone/EPO906
Study: NCT00323973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: 10 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bisoprolol
Description: 10 mg qd
Study: NCT01188408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome Entrapped Docetaxel (LE-DT)
Description: 110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
Study: NCT02063516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian Laryngeal Mask
Description: Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proseal Laryngeal Mask Airway
Description: Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
Study: NCT03301194

Intervention type: OTHER
Intervention: RAMP-HT
Description: RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
Study: NCT00048542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double-Blind Adalimumab/Placebo + MTX
Description: Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Double-Blind Adalimumab/Placebo + MTX
Description: Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double-Blind Adalimumab/Placebo
Description: Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Double-Blind Adalimumab/Placebo
Description: Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLE BSA Adalimumab +/- MTX
Description: Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLE BSA Adalimumab +/- MTX
Description: Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLE FD Adalimumab +/- MTX
Description: Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
Study: NCT01305551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablet, Oral, 500 mg, once on Day 1 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin XR FDC
Description: Tablet, Oral, 5/500 mg, once on Day 1 only
Study: NCT01213121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: oral tablet/25-600mg per day/once a day/six weeks
Study: NCT01582932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% Foam
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
Study: NCT04605120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical fusion
Description: 1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
Study: NCT04067687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative home visit
Description: a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
Study: NCT04953182

Intervention type: OTHER
Intervention: Pain scale registry
Description: The nurses ask the patient about the pain filling every two hours during the hospitalization.

Intervention type: OTHER
Intervention: Pain scale registry
Description: The nurses ask the patient about the pain filling every two hours during the hospitalization.
Study: NCT04364152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task walking training
Description: Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task walking training
Description: Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task walking training
Description: Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
Study: NCT01305551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin XR FDC
Description: Tablet, Oral, 5/500 mg, once on Day 1 only
Study: NCT03657745

Intervention type: DEVICE
Intervention: Combination of 40Hz light and cognitive therapy (ALZLIFE)
Description: Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE
Study: NCT04364152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task walking training
Description: Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
Study: NCT04109326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APAD
Description: 8 PA sessions supervised at the hospital centers and 44 unsupervised home sessions, to be performed twice a week.~6 consultations for nutrition education to teach the principles of well balanced diet, to foster weigh control during treatment, and to induce appropriate feeding behaviors after treatment.
Study: NCT03226470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T512
Description: T512 suppository contain 500 µg of T512 and suppocire.
Study: NCT05436730

Intervention type: DEVICE
Intervention: Sphygmocor
Description: Assessment of the arterial stiffness

Intervention type: DEVICE
Intervention: VaSera-VS
Description: Assessment of the arterial stiffness

Intervention type: DEVICE
Intervention: Somnocheck
Description: Assessment of the sleep breath disturbances
Study: NCT01571440

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No soluble corn fiber
Description: Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 12 g soluble corn fiber
Description: Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
Study: NCT02151890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
Study: NCT01587430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose ARA-C
Description: high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
Study: NCT00390806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYCAMTIN, oral capsules
Description: topotecan oral capsules 1.1 mg/m2
Study: NCT01587430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose ARA-C
Study: NCT00048542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLE FD Adalimumab +/- MTX
Description: Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
Study: NCT03707470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom fitted compression garments (CF)
Description: Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and \>20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-sized compression garments (SSG)
Description: Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 10 mmHg at both the ankle and thigh)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound (CON)
Description: Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
Study: NCT02255370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
Study: NCT00390806

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Whole brain radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Whole brain radiation
Study: NCT03180125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Description: median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound
Description: ultrasound guided injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound guided injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hyaluronate and 1% lidocain
Description: injection in the carpal tunnel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate and 1% lidocain
Description: injection in the carpal tunnel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid and 1%lidocain
Description: injection in the carpal tunnel
Study: NCT02745028

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Monosodium glutamate
Description: A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
Study: NCT03228212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL
Description: ACUVUE OASYS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL
Description: ACUVUE OASYS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST
Description: senofilcon A with new UV blocker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST
Description: senofilcon A with new UV blocker
Study: NCT02255370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin
Description: subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
Study: NCT02177682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
Study: NCT04519281

Intervention type: DRUG
Intervention: IV of vitamin C
Description: administration of high-dose of IV vitamin C perioperatively
Study: NCT00338923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HO/03/03
Study: NCT01043991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Study: NCT03231111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventive Multimedia Teaching Program
Description: Preventive Multimedia Teaching Program
Study: NCT04343157

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)
Description: In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.
Study: NCT01043991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04116125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Adjuvant radiotherapy on axillary region

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Adjuvant radiotherapy on axillary region
Study: NCT04606160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Problem-Solving Intervention
Description: The intervention will be a researcher led 30-45 minute session using the problem-solving module from the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Issues (MATCH-ADTC protocol.
Study: NCT03492034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IUD during CS
Description: IUD insertion during CS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IUD after puerperium
Description: IUD after puerperium
Study: NCT02069119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-108459

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03849222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apexification

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apexification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apexification

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apexification

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ca(OH)2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ca(OH)2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apical matrix
Description: collagen membrane (Biocollagen; Bioteck:Turin, Italy)
Study: NCT04436601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycols
Description: Polyethylene glycol will be administered to half of the study patients, and their response recorded and compared with that of the Lactulose arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Lactulose (standard of care) will be administered to half of the study patients and their response recorded.
Study: NCT03849222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apical matrix
Description: collagen membrane (Biocollagen; Bioteck:Turin, Italy)
Study: NCT03563196

Intervention type: RADIATION
Intervention: Chest Radiograph
Description: Chest radiogram will be obtained on day 1

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound will be done on day 1